MYR Pharma presents positive interim results in MYR 202 clinical trial
posted in Our news by myrcludex.admin
...
29
01, 18
0 Comments
posted in Our news by myrcludex.admin
...
posted in Our news by myrcludex.admin
Hepatera LLC and it`s development partner MYR GmbH today announced the initiation of MYR 202, a Phase 2b open label, randomized clinical trial to evaluate efficacy and safety of Myrcludex B in combination with tenofovir in chronically HBV/HDV сo-infected patients. 120 subjects will be enrolled in 20 centers in Russia and Germany.
posted in Our news by myrcludex.admin
Maxwell Biotech Portfolio Company Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic Hepatitis B and Delta
posted in Our news by myrcludex.admin
MAXWELL BIOTECH VENTURE FUND’S PORTFOLIO COMPANY HEPATERA COMPLETES ENROLLMENT OF PHASE IIA CLINICAL TRIAL OF MYRCLUDEX B, FOR HBV
posted in Our news by myrcludex.admin
Maxwell Biotech Venture Fund Invests in Hepatitis B/D Clinical Program
Co-Invests with Germany’s Public/Private High-Tech Gründerfonds, One of Europe’s Top Venture Funds